
Sign up to save your podcasts
Or


Tony Kulesa is a Co-founder @ Petri, an accelerator in Boston that backs companies developing new biotech applications and technologies in healthcare, food, industrial chemicals, and new materials. Co-founded and funded by Pillar, a venture firm co-founded by the CEOs of Cytyc, Ginkgo Bioworks, Iora Health, and 22 Boston companies, Petri draws on the resources of one of the strongest biotech ecosystems in the world to support founders from around the globe. Dr. Kulesa is an inventor and community builder. Previously, he was the founding Director of the MIT BioMakerspace, a community biology laboratory and incubator space, and an Instructor at the MIT Department of Biological Engineering. He holds a PhD from MIT, where his inventions of new platforms for drug discovery and microbial therapeutics were highlighted in Science Editor’s Choice and Nature Reviews Drug Discovery. While at MIT, he co-founded and directed 3 courses on biotech and entrepreneurship, including BiomedStartup, a course that coaches 10+ teams per year on research commercialization projects. He was a member of the founding officer team at MIT Biotech Group, and an ambassador for Breakout Labs, venture philanthropy from the Thiel Foundation to support companies bringing radical scientific discoveries out of the lab and into the market.
Topics:
The value of accelerators within the life sciences
Venture creation and innovation within biotech and pharma
Entering the life sciences industry from academia and other industries
The intersection of technology & biology: Silicon meets Boston & the profile of new funds straddling both philosophies
Types of risk within life sciences ventures: technical, biological, market
Impact of Covid-19 on the life sciences industry, both technological and financial
Investing and building in the life sciences revolution
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
Robert Pearl is the former CEO @ The Permanente Medical Group (1999-2017), the nation’s largest medical group, and former president of The Mid-Atlantic Permanente Medical Group (2009-2017). In these roles he led 10,000 physicians, 38,000 staff and was responsible for the nationally recognized medical care of 5 million Kaiser Permanente members on the west and east coasts. Dr. Pearl is nationally recognized as a physician leader on healthcare delivery. He hosts a popular podcast called Fixing Healthcare and is author of a Washington Post Bestseller: “Mistreated: why we think we’re getting good healthcare -- and why we’re usually wrong” (he has generously donated all the proceeds from his book to Doctors Without Borders). More recently, he has started a new weekly podcast - “Coronavirus: The Truth.” He writes regularly on Forbes and teaches at both the Stanford School of Medicine and Stanford Graduate School of Business. Dr. Pearl received his medical degree at Yale and completed a plastic surgery residency at Stanford. Visit his website to learn more.
Technology companies have increasingly focused on the healthcare system, and many are excited by their potential to drive change, decrease costs, and improve outcomes. Dr. Robert Pearl discusses hype versus reality in healthcare delivery innovation and how tech can help - but also hurt.
Topics:
How Kaiser Permanente has become a leader in quality, access, and price
The role of tech in the fee-for-service versus capitation debate
Disruption of the fee-for-service system coming from HAVEN, self-insured employers, and off-shore care partnerships
Hype versus reality in tech: how tech often approaches healthcare innovation wrong
The problem with wearables
Misaligned incentives within healthcare and tech
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
Rob Chess is a successful and esteemed serial biotech entrepreneur and executive. His resume is incredibly long and impressive. He is the Chairman of Nektar Therapeutics (NASDAQ: NKTR), a multi-billion dollar market cap company, where he was previously President and CEO. He is co-founder and Board member (until very recently the Chairman) of Biota Technologies, which uses DNA sequencing to optimize oil and gas production. He is a Lead Director at Twist Biosciences (NASDAQ: TWST), a public company that produces synthetic genes using an innovative high-throughput silicon-based manufacturing process. He was previously Chairman and CEO of OPX Biotechnologies, a renewable chemicals company that was sold to Cargill, and co-founder and President of Penederm, a dermatology company that went public and was acquired by Mylan Laboratories. He served in the White House in the first Bush administration, teaches at the Stanford business school, and is on the board of trustees at CalTech, and sits on the board of various other companies and organizations, among many other accomplishments.
The biopharma industry is undergoing immense change as there are exciting advancements in technology and life sciences, amidst a constantly changing structural environment. Rob Chess discusses keys for success for founders and executives and explores some key trends involving scale, platforms, financing, discovery, and payment reform within biopharma.
Topics:
Keys to success as a founder or executive in biotech
The cyclical nature of platforms, products, and financing in biotech as an industry
Scale in biopharma
The impact of tech-enabled services on biopharma
Direct-to-consumer biopharma
Eroom’s Law and drug discovery
Academia vs industry for life sciences innovation
Business model problems that belie the lack of successes in diagnostics
Incentive structures in healthcare and how to align them
Business school and management in healthcare and biopharma
Payment reform for specialty pharmaceuticals
Why go into healthcare?
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
Ian Tong is Chief Medical Officer @ Doctor On Demand. He is also currently Clinical Assistant Professor (Affiliated) at Stanford University Medical School. Ian has spent his career working to improve access to high quality care and brings this dedication to his work at Doctor On Demand.
Prior to joining Doctor On Demand, Ian held several medical leadership roles. He served as Stanford Internal Medicine Chief Resident; Co-Medical Director of the Arbor Free Clinic; and Founder and Medical Director of The Health Resource Initiative for Veterans Everywhere (THRIVE) at the VA Palo Alto Health Care System, which was honored in 2008 by the U.S. Secretary of Veterans Affairs with the Award for Outstanding Achievement in Service to Homeless Veterans. Before becoming Chief Medical Officer, Ian served as Medical Director at Doctor On Demand.
Ian is a National Collegiate Champion in Rugby at the University of California at Berkeley and was named to the All American Team in 1994. He graduated with a BA in English. He earned a medical degree from The University of Chicago – Pritzker and completed residency and Chief residency at Stanford Hospital and Clinics. He is board certified in Internal Medicine.
Ian lives in the San Francisco Bay Area with his wife and three children. He is most proud of the relationships he has built working alongside his family, friends, teammates, students and colleagues to positively impact the lives of others.
The COVID-19 pandemic is creating an inflection point in healthcare delivery and innovation. Telemedicine is playing a central role in combating the novel coronavirus outbreak, and the telehealth industry will emerge from the pandemic with new winners, losers, and structural changes.
Topics:
State of the pandemic and the role of telemedicine in combating it
The impact of COVID on the telehealth industry
Telemedicine winners and losers in aftermath of COVID: from point solutions to integrated longitudinal care
The power of retail clinics both during the pandemic and long term in telehealth and care delivery
Structural and policy changes needed for future pandemics and for the advancement of telemedicine
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
BIOS Podcast brings together cutting-edge insights from Life Science industry leaders at the forefront innovation.
Join us in hearing from Founders, Investors, Professors, & Pharma operating at the intersection of Technology & Biology.
By Alix Ventures: Driving Patient Impact - Supporting early stage Life Science startups engineering biology to drive radical advances in human health.
Learn more @ BIOS.community / Alix.vc
From the publisher's feed
BIOS Podcast brings together cutting-edge insights from Life Science industry leaders at the forefront of innovation.
Join us in hearing from Founders, Investors, Professors, & Pharma operating at the intersection of Technology & Biology.
By Alix Ventures: Driving Patient Impact - Supporting early stage Life Science startups engineering biology to drive radical advances in human health.
Learn more @ BIOS.community / Alix.vc
__________________________________
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.